دورية أكاديمية
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
| العنوان: | Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. |
|---|---|
| المؤلفون: | Wang SW; Department of Education, Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan., Hsieh TH; Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan., Cheng YM; Department of Gastroenterology and Hepatology, Tung's Taichung MetroHarbor Hospital, Taichung, Taiwan., Wang CC; Department of Gastroenterology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, New Taipei City and Hualien, Taiwan. wangchiachi888@gmail.com.; Medical Department, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, 289 Jianguo Rd., Xindian Area, New Taipei City, 23142, Taiwan. wangchiachi888@gmail.com., Kao JH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. |
| المصدر: | Hepatology international [Hepatol Int] 2024 Jun; Vol. 18 (3), pp. 943-951. Date of Electronic Publication: 2024 Jan 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Springer |
| مواضيع طبية MeSH: | Non-alcoholic Fatty Liver Disease*/complications , Non-alcoholic Fatty Liver Disease*/epidemiology , Non-alcoholic Fatty Liver Disease*/diagnostic imaging , Atherosclerosis*/complications , Atherosclerosis*/epidemiology , Atherosclerosis*/diagnostic imaging, Humans ; Male ; Female ; Middle Aged ; Taiwan/epidemiology ; Risk Factors ; Aged ; Adult ; Ultrasonography ; Fatty Liver/complications ; Fatty Liver/epidemiology ; Fatty Liver/diagnostic imaging ; Liver/pathology ; Liver/diagnostic imaging ; Liver Cirrhosis/complications |
| مستخلص: | Background and Aims: In 2023, a new nomenclature of "metabolic associated steatotic liver disease" (MASLD) has emerged by incorporating cardio-metabolic criteria to redefine "non-alcoholic fatty liver disease" (NAFLD). Among steatotic liver disease (SLD), those having no known causes and without any one of cardio-metabolic criteria are deemed to have cryptogenic SLD. This study aims to compare the liver and atherosclerotic risks between MASLD and cryptogenic SLD patients. Approach: We analyzed participants with liver ultrasound data from the Taiwan Bio-Bank cohort, excluding those with positive HBsAg, positive anti-HCV, or "frequent drinker". MASLD involves hepatic steatosis and any of five cardiometabolic risk factors, whereas cryptogenic SLD features hepatic steatosis without these risk factors. Liver fibrosis severity was assessed by using NAFLD fibrosis score (NFS), while atherosclerosis was determined by carotid plaques on duplex ultrasound. Results: Among 17,595 subjects (age 55.47 ± 10.41; males 31.8%), 7538 participants (42.8%) had SLD, comprising 96.5% of MASLD and 3.5% of cryptogenic SLD. Cryptogenic SLD patients are younger and had a lower percentage of male than those with MASLD. After propensity score matching for age and sex, patients with cryptogenic SLD exhibited milder glucose and lipid profiles, fewer carotid plaques, lower liver steatosis, inflammation, and fibrosis markers than those with MASLD. Conclusions: In this large population-based study, cryptogenic SLD, the excluded group, occupy only 3.5% in NAFLD patients. It has lower liver and atherosclerotic risks than MASLD, supporting its exclusion from NAFLD and justifying the rationale for the new disease name and diagnostic criteria of MASLD. (© 2024. Asian Pacific Association for the Study of the Liver.) |
| References: | Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https://doi.org/10.1097/HEP.0000000000000696. (PMID: 10.1097/HEP.000000000000069637984709) Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000696. (PMID: 10.1097/HEP.000000000000069638445559) Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023. https://doi.org/10.1097/HEP.0000000000000696. (PMID: 10.1097/HEP.000000000000069637364816) Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014. (PMID: 10.1053/j.gastro.2019.11.31232044314) Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. (PMID: 10.1016/j.jhep.2020.03.03932278004) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. (PMID: 10.1161/CIRCULATIONAHA.109.19264419805654) Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. (PMID: 10.1007/s12072-020-10094-233006093) Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112. (PMID: 10.1002/hep.2097316447287) Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109–1117. (PMID: 10.1016/j.ijcard.2012.09.08523141876) Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10:329–338. (PMID: 10.14218/JCTH.2021.0017835528971) Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol. 2023;S0168–8278(23):05055–05059. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43:2425–2433. (PMID: 10.1111/liv.1569537592856) Fan CT, Lin JC, Lee CH. Taiwan biobank: a project aiming to aid Taiwan’s transition into a biomedical island. Pharmacogenomics. 2008;9:235–246. (PMID: 10.2217/14622416.9.2.23518370851) Lin JC, Fan CT, Liao CC, Chen YS. Taiwan biobank: making cross-database convergence possible in the big data era. Gigascience. 2018;7:1–4. (PMID: 10.1093/gigascience/gix11029635374) Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int. 2023;17:350–356. (PMID: 10.1007/s12072-022-10449-x36471232) Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061–1067. (PMID: 10.1016/j.jhep.2009.09.001198462346136148) Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;2(6):33. (PMID: 10.1186/1471-230X-6-33) Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. (PMID: 10.1002/hep.2149617393509) Kabłak-Ziembicka A, Przewłocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events in primary and secondary care patients. J Clin Med. 2021;10(20):4628. (PMID: 10.3390/jcm10204628346827518538659) Wang CC, Cheng YM, Kao JH. Letter to the Editor: Statement of steatotic liver disease: a great leap towards the global standardization. Hepatology. 2023;79:E7–E8. (PMID: 10.1097/HEP.000000000000055537535804) Bedoogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. (PMID: 10.1186/1471-230X-6-33) Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;28(65): 102292. (PMID: 10.1016/j.eclinm.2023.102292) Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–1044. (PMID: 10.1002/hep.2274219243014) Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061–1067. (PMID: 10.1016/j.jhep.2009.09.001198462346136148) Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503–508. (PMID: 10.1016/j.dld.2009.08.00219766548) |
| معلومات مُعتمدة: | TCRD-TPE-112-11 Taipei Tzu Chi Hospital; TCRD-TPE-112-RT-7 Taipei Tzu Chi Hospital; MOHW112-TDU-B-211-144002 Taiwan Liver Disease Consortium |
| فهرسة مساهمة: | Keywords: Metabolic associated steatotic liver disease; Metabolic dysfunction; NAFLD fibrosis score; Non-alcoholic fatty liver disease; Steatotic liver disease |
| تواريخ الأحداث: | Date Created: 20240116 Date Completed: 20240524 Latest Revision: 20240708 |
| رمز التحديث: | 20240708 |
| DOI: | 10.1007/s12072-023-10624-8 |
| PMID: | 38227142 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1936-0541 |
|---|---|
| DOI: | 10.1007/s12072-023-10624-8 |